Patents by Inventor Bettina Ploder

Bettina Ploder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of patients with severe von Willebrand disease undergoing elective surgery by administration of recombinant VWF
    Patent number: 12622950
    Abstract: The present invention relates to method for pretreating a subject with severe von Willebrand disease prior to a surgical procedure comprising administering to the subject a dose ranging from about 20 IU/kg to about 60 IU/kg rVWF between about 12 hours and about 24 hours prior to the surgical procedure, and wherein Factor VIII is not administered with the rVWF prior to the surgical procedure.
    Type: Grant
    Filed: December 8, 2021
    Date of Patent: May 12, 2026
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Miranda Chapman, Bruce Ewenstein, Bettina Ploder
  • TREATMENT OF GASTROINTESTINAL BLEEDING IN PATIENTS WITH SEVERE VON WILLEBRAND DISEASE BY ADMINISTRATION OF RECOMBINANT VWF
    Publication number: 20240316160
    Abstract: The present invention relates to a method for treating gastrointestinal bleeding in a subject with severe von Willebrand Disease comprising administering to the subject at least one dose of recombinant von Willebrand Factor (rVWF) ranging from about 40 IU/kg to about 100 IU/kg, wherein the first dose further comprises recombinant Factor VIII (rFVIII).
    Type: Application
    Filed: June 12, 2024
    Publication date: September 26, 2024
    Inventors: Miranda Chapman, Bruce Ewenstein, Bettina Ploder
  • Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF
    Patent number: 12016904
    Abstract: The present invention relates to a method for treating gastrointestinal bleeding in a subject with severe von Willebrand Disease comprising administering to the subject at least one dose of recombinant von Willebrand Factor (rVWF) ranging from about 40 IU/kg to about 100 IU/kg, wherein the first dose further comprises recombinant Factor VIII (rFVIII).
    Type: Grant
    Filed: December 6, 2022
    Date of Patent: June 25, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Miranda Chapman, Bruce Ewenstein, Bettina Ploder
  • TREATMENT OF PATIENTS WITH SEVERE VON WILLEBRAND DISEASE UNDERGOING ELECTIVE SURGERY BY ADMINISTRATION OF RECOMBINANT VWF
    Publication number: 20240009279
    Abstract: The present invention relates to method for pretreating a subject with severe von Willebrand disease prior to a surgical procedure comprising administering to the subject a dose ranging from about 20 IU/kg to about 60 IU/kg rVWF between about 12 hours and about 24 hours prior to the surgical procedure, and wherein Factor VIII is not administered with the rVWF prior to the surgical procedure.
    Type: Application
    Filed: May 12, 2023
    Publication date: January 11, 2024
    Inventors: Miranda Chapman, Bruce Ewenstein, Bettina Ploder
  • TREATMENT OF MENORRHAGIA IN PATIENTS WITH SEVERE VON WILLEBRAND DISEASE BY ADMINISTRATION OF RECOMBINANT VWF
    Publication number: 20230398188
    Abstract: The present invention relates to a method for treatment of menorrhagia in a subject with von Willebrand Disease (VWD) comprising administering a therapeutic amount of recombinant von Willebrand Factor (rVWF) to the subject.
    Type: Application
    Filed: February 4, 2021
    Publication date: December 14, 2023
    Inventors: Bettina Ploder, Françoise Truong-Berthoz
  • TREATMENT OF GASTROINTESTINAL BLEEDING IN PATIENTS WITH SEVERE VON WILLEBRAND DISEASE BY ADMINISTRATION OF RECOMBINANT VWF
    Publication number: 20230122958
    Abstract: The present invention relates to a method for treating gastrointestinal bleeding in a subject with severe von Willebrand Disease comprising administering to the subject at least one dose of recombinant von Willebrand Factor (rVWF) ranging from about 40 IU/kg to about 100 IU/kg, wherein the first dose further comprises recombinant Factor VIII (rFVIII).
    Type: Application
    Filed: December 6, 2022
    Publication date: April 20, 2023
    Inventors: Miranda Chapman, Bruce Ewenstein, Bettina Ploder
  • Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF
    Patent number: 11529395
    Abstract: The present invention relates to a method for treating gastrointestinal bleeding in a subject with severe von Willebrand Disease comprising administering to the subject at least one dose of recombinant von Willebrand Factor (rVWF) ranging from about 40 IU/kg to about 100 IU/kg, wherein the first dose further comprises recombinant Factor VIII (rFVIII).
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: December 20, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Miranda Chapman, Bruce Ewenstein, Bettina Ploder
  • TREATMENT OF PATIENTS WITH SEVERE VON WILLEBRAND DISEASE UNDERGOING ELECTIVE SURGERY BY ADMINISTRATION OF RECOMBINANT VWF
    Publication number: 20220168397
    Abstract: The present invention relates to method for pretreating a subject with severe von Willebrand disease prior to a surgical procedure comprising administering to the subject a dose ranging from about 20 IU/kg to about 60 IU/kg rVWF between about 12 hours and about 24 hours prior to the surgical procedure, and wherein Factor VIII is not administered with the rVWF prior to the surgical procedure.
    Type: Application
    Filed: December 8, 2021
    Publication date: June 2, 2022
    Inventors: Miranda Chapman, Bruce Ewenstein, Bettina Ploder
  • TREATMENT OF GASTROINTESTINAL BLEEDING IN PATIENTS WITH SEVERE VON WILLEBRAND DISEASE BY ADMINISTRATION OF RECOMBINANT VWF
    Publication number: 20210169989
    Abstract: The present invention relates to a method for treating gastrointestinal bleeding in a subject with severe von Willebrand Disease comprising administering to the subject at least one dose of recombinant von Willebrand Factor (rVWF) ranging from about 40 IU/kg to about 100 IU/kg, wherein the first dose further comprises recombinant Factor VIII (rFVIII).
    Type: Application
    Filed: December 1, 2020
    Publication date: June 10, 2021
    Inventors: Miranda Chapman, Bruce Ewenstein, Bettina Ploder
  • Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF
    Patent number: 10905746
    Abstract: The present invention relates to a method for treating gastrointestinal bleeding in a subject with severe von Willebrand Disease comprising administering to the subject at least one dose of recombinant von Willebrand Factor (rVWF) ranging from about 40 IU/kg to about 100 IU/kg, wherein the first dose further comprises recombinant Factor VIII (rFVIII).
    Type: Grant
    Filed: February 26, 2020
    Date of Patent: February 2, 2021
    Assignees: Baxalta GmbH, Baxalta Incorporated
    Inventors: Miranda Chapman, Bruce Ewenstein, Bettina Ploder
  • TREATMENT OF GASTROINTESTINAL BLEEDING IN PATIENTS WITH SEVERE VON WILLEBRAND DISEASE BY ADMINISTRATION OF RECOMBINANT VWF
    Publication number: 20200206318
    Abstract: The present invention relates to a method for treating gastrointestinal bleeding in a subject with severe von Willebrand Disease comprising administering to the subject at least one dose of recombinant von Willebrand Factor (rVWF) ranging from about 40 IU/kg to about 100 IU/kg, wherein the first dose further comprises recombinant Factor VIII (rFVIII).
    Type: Application
    Filed: February 26, 2020
    Publication date: July 2, 2020
    Inventors: Miranda Chapman, Bruce Ewenstein, Bettina Ploder
  • Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF
    Patent number: 10632176
    Abstract: The present invention relates to a method for treating gastrointestinal bleeding in a subject with severe von Willebrand Disease comprising administering to the subject at least one dose of recombinant von Willebrand Factor (rVWF) ranging from about 40 IU/kg to about 100 IU/kg, wherein the first dose further comprises recombinant Factor VIII (rFVIII).
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: April 28, 2020
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Miranda Chapman, Bruce Ewenstein, Bettina Ploder
  • TREATMENT OF PATIENTS WITH SEVERE VON WILLEBRAND DISEASE UNDERGOING ELECTIVE SURGERY BY ADMINISTRATION OF RECOMBINANT VWF
    Publication number: 20190091298
    Abstract: The present invention relates to method for pretreating a subject with severe von Willebrand disease prior to a surgical procedure comprising administering to the subject a dose ranging from about 20 IU/kg to about 60 IU/kg rVWF between about 12 hours and about 24 hours prior to the surgical procedure, and wherein Factor VIII is not administered with the rVWF prior to the surgical procedure.
    Type: Application
    Filed: July 9, 2018
    Publication date: March 28, 2019
    Inventors: Miranda Chapman, Bruce Ewenstein, Bettina Ploder
  • TREATMENT OF GASTROINTESTINAL BLEEDING IN PATIENTS WITH SEVERE VON WILLEBRAND DISEASE BY ADMINISTRATION OF RECOMBINANT VWF
    Publication number: 20190091299
    Abstract: The present invention relates to a method for treating gastrointestinal bleeding in a subject with severe von Willebrand Disease comprising administering to the subject at least one dose of recombinant von Willebrand Factor (rVWF) ranging from about 40 IU/kg to about 100 IU/kg, wherein the first dose further comprises recombinant Factor VIII (rFVIII).
    Type: Application
    Filed: July 9, 2018
    Publication date: March 28, 2019
    Inventors: Miranda Chapman, Bruce Ewenstein, Bettina Ploder